Thermo Fisher Scientific Inc. $TMO Stock Purchased by Russell Investments Group Ltd.

Russell Investments Group Ltd. grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 351,042 shares of the medical research company’s stock after purchasing an additional 13,133 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.09% of Thermo Fisher Scientific worth $237,133,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Allspring Global Investments Holdings LLC lifted its holdings in shares of Thermo Fisher Scientific by 9.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 140,228 shares of the medical research company’s stock valued at $91,500,000 after acquiring an additional 12,414 shares in the last quarter. Leelyn Smith LLC increased its holdings in Thermo Fisher Scientific by 0.8% in the 3rd quarter. Leelyn Smith LLC now owns 9,789 shares of the medical research company’s stock valued at $6,608,000 after purchasing an additional 77 shares in the last quarter. Parallel Advisors LLC raised its position in Thermo Fisher Scientific by 0.4% in the third quarter. Parallel Advisors LLC now owns 37,831 shares of the medical research company’s stock valued at $25,538,000 after purchasing an additional 137 shares during the period. Mader & Shannon Wealth Management Inc. raised its position in Thermo Fisher Scientific by 1.7% in the third quarter. Mader & Shannon Wealth Management Inc. now owns 18,775 shares of the medical research company’s stock valued at $12,674,000 after purchasing an additional 316 shares during the period. Finally, International Assets Investment Management LLC lifted its stake in shares of Thermo Fisher Scientific by 3,023.3% during the third quarter. International Assets Investment Management LLC now owns 170,000 shares of the medical research company’s stock worth $114,758,000 after purchasing an additional 164,557 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

TMO has been the topic of a number of recent analyst reports. Leerink Partners upped their target price on Thermo Fisher Scientific from $600.00 to $620.00 and gave the company an “outperform” rating in a research report on Wednesday, July 22nd. Barclays increased their target price on Thermo Fisher Scientific from $750.00 to $775.00 and gave the stock an “overweight” rating in a research report on Thursday, October 22nd. Morgan Stanley lifted their target price on Thermo Fisher Scientific from $650.00 to $730.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. Argus increased their price objective on shares of Thermo Fisher Scientific from $560.00 to $780.00 and gave the company a “buy” rating in a report on Friday, October 30th. Finally, CLSA assumed coverage on shares of Thermo Fisher Scientific in a research report on Thursday, September 3rd. They issued an “outperform” rating and a C$748.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $683.64.

Thermo Fisher Scientific Trading Down 2.5%

Shares of Thermo Fisher Scientific stock opened at $699.55 on Friday. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $727.56. The company has a 50-day simple moving average of $669.20 and a 200 day simple moving average of $556.44. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $259.20 billion, a P/E ratio of 29.03, a price-to-earnings-growth ratio of 2.92 and a beta of 0.84.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 21st. The medical research company reported $6.68 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $0.28. Thermo Fisher Scientific had a return on equity of 17.33% and a net margin of 14.94%. The firm had revenue of $12.14 billion during the quarter, compared to analyst estimates of $11.95 billion. During the same period last year, the company earned $5.79 earnings per share. The company’s revenue was up 9.1% on a year-over-year basis. Research analysts expect that Thermo Fisher Scientific Inc. will post 25.27 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 15th. Investors of record on Tuesday, December 15th will be given a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is currently 9.92%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 275 shares of Thermo Fisher Scientific stock in a transaction on Monday, August 24th. The stock was sold at an average price of $627.05, for a total value of $172,438.75. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $77,707,171.25. The trade was a 0.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 2,831 shares of the firm’s stock in a transaction dated Wednesday, October 28th. The shares were sold at an average price of $706.45, for a total value of $1,999,959.95. Following the completion of the sale, the vice president directly owned 11,560 shares in the company, valued at $8,166,562. This trade represents a 19.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 24,546 shares of company stock worth $15,479,192. Company insiders own 0.33% of the company’s stock.

Latest Thermo Fisher Scientific News

Investors following TMO have been watching these news items:

• Positive Sentiment: A report discusses Thermo Fisher’s $5 billion buyback, putting its cash generation and capital returns in focus. Repurchases can support per-share results and signal confidence, though the article also questions whether cash flows justify expectations after the stock’s strong multiyear return. Is Thermo Fisher Scientific Reasonable After Its $5 Billion Buyback?
• Neutral Sentiment: Industry reports project growth in markets where Thermo Fisher competes, including single-use bioprocessing, cell lysis and cell-culture coatings. These forecasts suggest favorable longer-term demand, but are broad market estimates—not evidence of new orders or a change in the company’s outlook. Single-Use Bioprocessing Market Report
• Neutral Sentiment: Other coverage notes TMO’s strong recent share performance and considers whether its cash generation can sustain investor expectations. That highlights potential valuation sensitivity, but provides no new earnings warning or negative company announcement. What Happened To People Who Bought Thermo Fisher Stock At A High?

About Thermo Fisher Scientific

Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research. The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.